DrugBank

FEBRUARY 19, 2025

billion by 2030, the sector is witnessing a shift in how drugs are conceived, developed, and tested.  This discovery highlights how AI can uncover new biological insights and enable the development of targeted therapies for diseases with unmet medical needs. billion in 2023 to $7.9

Clinical Trials 52

Clinical Trials Drugs Trials Treatment 52

Vial

MAY 20, 2024

billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030. The role of this type of CRO is pivotal in the drug development process to determine whether a new therapy is well-tolerated in the general population over a longer period of time. What is a Pre-Clinical CRO? over this period.

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

The Pharma Data

SEPTEMBER 16, 2020

SLB linked to 2025 Patient Access Targets to increase patients reached in low- and middle-income countries (LMICs) with strategic innovative therapies by 200% and the Novartis Flagship Programs by 50%. Novartis is taking bold steps to increase patient reach in LMICs with its strategic innovative therapies by at least 200% by 2025.

Therapies 52

Therapies Regulations Government Disease 52

The Pharma Data

JULY 27, 2021

AbbVie (NYSE: ABBV) and Calico Life Sciences today announced an extension of their leading-edge collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. This is the second extension of the collaboration originally established in 2014.

Disease 52

Disease Science Therapies Production 52

The Pharma Data

MARCH 13, 2021

. “A key insight of the results from the TRAILBLAZER-ALZ study is that donanemab not only significantly reduced the amount of amyloid deposition in these patients but also slowed the clinical progression of the disease suggesting that this could be a disease-modifying therapy. Source link:[link].

Disease 40

Disease Trials Treatment Medical Schools 40

Broad Institute

JUNE 24, 2025

Muldoon, a baby boy born without the ability to process dietary protein properly, had become the first person to be treated with a customized gene editing therapy. wasn’t the first patient to receive base editing therapy. He needed a personalized, one-of-a-kind therapy.

Treatment 133

Treatment Disease DNA Clinical Trials 133

PPD

APRIL 14, 2025

This expansion is creating opportunities for clinical trials related to a range of new therapy areas and their subpopulations. However, it is representative of the average across most of todays trials, where only 2030% of participants are women. Food and Drug Administrations (FDA) diversity and inclusion in clinical trials mandate.

Clinical Trials 52

Clinical Trials Trials Clinical Development Disease 52

Codon

MARCH 24, 2024

market with Wegovy will, by 2030, require about one million liters of production capacity. In response to this hysteria, regulation was aggressively tightened. Cirsium Bio is using plants to produce viral vectors for gene therapy. The total global bioprocessing capacity was estimated at 17.4

Engineering 87

Engineering Vaccine Production RNA 87

PPD

JANUARY 21, 2025

As 2025 kicks off, the biopharma and biotech industries find themselves at a pivotal juncture, navigating an era of rapid transformation marked by new technological advancements, evolving regulations and shifting industry priorities. This is especially critical in managing complex therapies, where precision and safety are paramount.

Clinical Trials 52

Clinical Trials Trials Clinical Research Drug Development 52